+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Human Papillomavirus Vaccine Market Research Report by Indication (Anal Cancer, Cervical Cancer, and Genital Warts), Valance, Distribution Channel, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2027 - Cumulative Impact of COVID-19

  • ID: 4858029
  • Report
  • April 2022
  • Region: Global
  • 216 Pages
  • 360iResearch™
UP TO OFF until Dec 31st 2022

FEATURED COMPANIES

  • AstraZeneca PLC
  • Bavarian Nordic A/S
  • Eyegene lnc. Ltd.
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Merck Sharp & Dohme Corp.
The Global Human Papillomavirus Vaccine Market size was estimated at USD 3,773.09 million in 2021, USD 4,027.96 million in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 6.93% to reach USD 5,640.87 million by 2027.



Market Statistics:


The report provides market sizing and forecast across five major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Human Papillomavirus Vaccine to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Indication, the market was studied across Anal Cancer, Cervical Cancer, Genital Warts, Oropharyngeal Cancer, Penile Cancer, Vaginal Cancer, and Vulvar Cancer.
  • Based on Valance, the market was studied across Bivalent and Quadrivalent and Nonavalent.
  • Based on Distribution Channel, the market was studied across Government Entities, Physicians, Public and Private Alliances, and Wholesalers.
  • Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:


We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.

This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Human Papillomavirus Vaccine market considering the current update on the conflict and its global response.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Human Papillomavirus Vaccine Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:


The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Human Papillomavirus Vaccine Market, including A-S Medication Solutions, LLC, AstraZeneca PLC, Bavarian Nordic A/S, Eyegene lnc. Ltd., GlaxoSmithKline PLC, Inovio Pharmaceuticals Inc., Johnson & Johnson, Merck Sharp & Dohme Corp., Pfizer Inc., and Sanofi S.A..

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the Global Human Papillomavirus Vaccine Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Human Papillomavirus Vaccine Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Human Papillomavirus Vaccine Market?
4. What is the competitive strategic window for opportunities in the Global Human Papillomavirus Vaccine Market?
5. What are the technology trends and regulatory frameworks in the Global Human Papillomavirus Vaccine Market?
6. What is the market share of the leading vendors in the Global Human Papillomavirus Vaccine Market?
7. What modes and strategic moves are considered suitable for entering the Global Human Papillomavirus Vaccine Market?
Frequently Asked Questions about the Global Human Papillomavirus Vaccine Market

What is the estimated value of the Global Human Papillomavirus Vaccine Market?

The Global Human Papillomavirus Vaccine Market was estimated to be valued at $3773.1 Million in 2021.

What is the growth rate of the Global Human Papillomavirus Vaccine Market?

The growth rate of the Global Human Papillomavirus Vaccine Market is 6.9%, with an estimated value of $5640.9 Million by 2027.

What is the forecasted size of the Global Human Papillomavirus Vaccine Market?

The Global Human Papillomavirus Vaccine Market is estimated to be worth $5640.9 Million by 2027.

Who are the key companies in the Global Human Papillomavirus Vaccine Market?

Key companies in the Global Human Papillomavirus Vaccine Market include A, S Medication Solutions, LLC, AstraZeneca PLC, Bavarian Nordic A/S, Eyegene lnc. Ltd., GlaxoSmithKline PLC, Inovio Pharmaceuticals Inc., Johnson & Johnson and Pfizer Inc..
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AstraZeneca PLC
  • Bavarian Nordic A/S
  • Eyegene lnc. Ltd.
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Merck Sharp & Dohme Corp.

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Human papillomavirus vaccines associated uses for treatment of cancer
5.1.1.2. Widely commended as a sweeping pharmaceutical innovation
5.1.2. Restraints
5.1.2.1. Inadequate delivery of infrastructure
5.1.2.2. Affordability and sustainable financing of HPV vaccination
5.1.3. Opportunities
5.1.3.1. Funding by the government on the R&D department of cancer
5.1.3.2. Growing support for HPV introduction among the global health community
5.1.3.3. Reductions in the incidence of genital warts and high-grade precancerous lesions
5.1.4. Challenges
5.1.4.1. Lack of community engagement to generate awareness regarding diagnosis and treatment of HPV
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of 2022 Russia Ukraine Conflict
6. Human Papillomavirus Vaccine Market, by Indication
6.1. Introduction
6.2. Anal Cancer
6.3. Cervical Cancer
6.4. Genital Warts
6.5. Oropharyngeal Cancer
6.6. Penile Cancer
6.7. Vaginal Cancer
6.8. Vulvar Cancer
7. Human Papillomavirus Vaccine Market, by Valance
7.1. Introduction
7.2. Bivalent
7.3. Quadrivalent and Nonavalent
8. Human Papillomavirus Vaccine Market, by Distribution Channel
8.1. Introduction
8.2. Government Entities
8.3. Physicians
8.4. Public and Private Alliances
8.5. Wholesalers
9. Americas Human Papillomavirus Vaccine Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Human Papillomavirus Vaccine Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
11. Europe, Middle East & Africa Human Papillomavirus Vaccine Market
11.1. Introduction
11.2. France
11.3. Germany
11.4. Italy
11.5. Netherlands
11.6. Qatar
11.7. Russia
11.8. Saudi Arabia
11.9. South Africa
11.10. Spain
11.11. United Arab Emirates
11.12. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. A-S Medication Solutions, LLC
13.2. AstraZeneca PLC
13.3. Bavarian Nordic A/S
13.4. Eyegene lnc. Ltd.
13.5. GlaxoSmithKline PLC
13.6. Inovio Pharmaceuticals Inc.
13.7. Johnson & Johnson
13.8. Merck Sharp & Dohme Corp.
13.9. Pfizer Inc.
13.10. Sanofi S.A.
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
List of Figures
FIGURE 1. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET: DYNAMICS
FIGURE 2. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY INDICATION, 2021 VS 2027 (%)
FIGURE 3. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY INDICATION, 2021 VS 2027 (USD MILLION)
FIGURE 4. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY INDICATION, 2027
FIGURE 5. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY ANAL CANCER, 2019-2027 (USD MILLION)
FIGURE 6. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY ANAL CANCER, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 7. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY CERVICAL CANCER, 2019-2027 (USD MILLION)
FIGURE 8. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 9. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENITAL WARTS, 2019-2027 (USD MILLION)
FIGURE 10. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENITAL WARTS, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 11. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY OROPHARYNGEAL CANCER, 2019-2027 (USD MILLION)
FIGURE 12. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY OROPHARYNGEAL CANCER, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 13. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY PENILE CANCER, 2019-2027 (USD MILLION)
FIGURE 14. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY PENILE CANCER, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 15. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VAGINAL CANCER, 2019-2027 (USD MILLION)
FIGURE 16. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VAGINAL CANCER, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 17. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VULVAR CANCER, 2019-2027 (USD MILLION)
FIGURE 18. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VULVAR CANCER, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 19. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VALANCE, 2021 VS 2027 (%)
FIGURE 20. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VALANCE, 2021 VS 2027 (USD MILLION)
FIGURE 21. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VALANCE, 2027
FIGURE 22. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY BIVALENT, 2019-2027 (USD MILLION)
FIGURE 23. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY BIVALENT, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 24. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY QUADRIVALENT AND NONAVALENT, 2019-2027 (USD MILLION)
FIGURE 25. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY QUADRIVALENT AND NONAVALENT, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 26. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2021 VS 2027 (%)
FIGURE 27. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2021 VS 2027 (USD MILLION)
FIGURE 28. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2027
FIGURE 29. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GOVERNMENT ENTITIES, 2019-2027 (USD MILLION)
FIGURE 30. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GOVERNMENT ENTITIES, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 31. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY PHYSICIANS, 2019-2027 (USD MILLION)
FIGURE 32. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY PHYSICIANS, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 33. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY PUBLIC AND PRIVATE ALLIANCES, 2019-2027 (USD MILLION)
FIGURE 34. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY PUBLIC AND PRIVATE ALLIANCES, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 35. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY WHOLESALERS, 2019-2027 (USD MILLION)
FIGURE 36. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY WHOLESALERS, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 37. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 38. ARGENTINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 39. BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 40. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 41. MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 42. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 43. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 44. AUSTRALIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 45. CHINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 46. INDIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 47. INDONESIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 48. JAPAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 49. MALAYSIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 50. PHILIPPINES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 51. SINGAPORE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 52. SOUTH KOREA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 53. TAIWAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 54. THAILAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 55. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 56. FRANCE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 57. GERMANY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 58. ITALY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 59. NETHERLANDS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 60. QATAR HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 61. RUSSIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 62. SAUDI ARABIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 63. SOUTH AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 64. SPAIN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 65. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 66. UNITED KINGDOM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 67. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET: FPNV POSITIONING MATRIX
FIGURE 68. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET: SHARE, BY KEY PLAYER, 2021
FIGURE 69. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE
List of Tables
TABLE 1. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY INDICATION, 2019-2027 (USD MILLION)
TABLE 4. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY ANAL CANCER, BY REGION, 2019-2027 (USD MILLION)
TABLE 5. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY ANAL CANCER, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 6. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY ANAL CANCER, BY STATE, 2019-2027 (USD MILLION)
TABLE 7. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY ANAL CANCER, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 8. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY ANAL CANCER, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 9. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2019-2027 (USD MILLION)
TABLE 10. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY CERVICAL CANCER, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 11. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY CERVICAL CANCER, BY STATE, 2019-2027 (USD MILLION)
TABLE 12. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY CERVICAL CANCER, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 13. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY CERVICAL CANCER, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 14. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENITAL WARTS, BY REGION, 2019-2027 (USD MILLION)
TABLE 15. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENITAL WARTS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 16. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENITAL WARTS, BY STATE, 2019-2027 (USD MILLION)
TABLE 17. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENITAL WARTS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 18. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENITAL WARTS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 19. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY OROPHARYNGEAL CANCER, BY REGION, 2019-2027 (USD MILLION)
TABLE 20. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY OROPHARYNGEAL CANCER, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 21. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY OROPHARYNGEAL CANCER, BY STATE, 2019-2027 (USD MILLION)
TABLE 22. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY OROPHARYNGEAL CANCER, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 23. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY OROPHARYNGEAL CANCER, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 24. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY PENILE CANCER, BY REGION, 2019-2027 (USD MILLION)
TABLE 25. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY PENILE CANCER, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 26. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY PENILE CANCER, BY STATE, 2019-2027 (USD MILLION)
TABLE 27. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY PENILE CANCER, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 28. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY PENILE CANCER, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 29. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VAGINAL CANCER, BY REGION, 2019-2027 (USD MILLION)
TABLE 30. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VAGINAL CANCER, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 31. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VAGINAL CANCER, BY STATE, 2019-2027 (USD MILLION)
TABLE 32. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VAGINAL CANCER, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 33. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VAGINAL CANCER, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 34. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VULVAR CANCER, BY REGION, 2019-2027 (USD MILLION)
TABLE 35. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VULVAR CANCER, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 36. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VULVAR CANCER, BY STATE, 2019-2027 (USD MILLION)
TABLE 37. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VULVAR CANCER, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 38. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VULVAR CANCER, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 39. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VALANCE, 2019-2027 (USD MILLION)
TABLE 40. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY BIVALENT, BY REGION, 2019-2027 (USD MILLION)
TABLE 41. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY BIVALENT, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 42. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY BIVALENT, BY STATE, 2019-2027 (USD MILLION)
TABLE 43. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY BIVALENT, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 44. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY BIVALENT, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 45. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY QUADRIVALENT AND NONAVALENT, BY REGION, 2019-2027 (USD MILLION)
TABLE 46. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY QUADRIVALENT AND NONAVALENT, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 47. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY QUADRIVALENT AND NONAVALENT, BY STATE, 2019-2027 (USD MILLION)
TABLE 48. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY QUADRIVALENT AND NONAVALENT, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 49. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY QUADRIVALENT AND NONAVALENT, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 50. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 51. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GOVERNMENT ENTITIES, BY REGION, 2019-2027 (USD MILLION)
TABLE 52. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GOVERNMENT ENTITIES, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 53. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GOVERNMENT ENTITIES, BY STATE, 2019-2027 (USD MILLION)
TABLE 54. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GOVERNMENT ENTITIES, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 55. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GOVERNMENT ENTITIES, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 56. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY PHYSICIANS, BY REGION, 2019-2027 (USD MILLION)
TABLE 57. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY PHYSICIANS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 58. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY PHYSICIANS, BY STATE, 2019-2027 (USD MILLION)
TABLE 59. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY PHYSICIANS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 60. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY PHYSICIANS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 61. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY PUBLIC AND PRIVATE ALLIANCES, BY REGION, 2019-2027 (USD MILLION)
TABLE 62. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY PUBLIC AND PRIVATE ALLIANCES, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 63. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY PUBLIC AND PRIVATE ALLIANCES, BY STATE, 2019-2027 (USD MILLION)
TABLE 64. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY PUBLIC AND PRIVATE ALLIANCES, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 65. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY PUBLIC AND PRIVATE ALLIANCES, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 66. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY WHOLESALERS, BY REGION, 2019-2027 (USD MILLION)
TABLE 67. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY WHOLESALERS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 68. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY WHOLESALERS, BY STATE, 2019-2027 (USD MILLION)
TABLE 69. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY WHOLESALERS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 70. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY WHOLESALERS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 71. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 72. ARGENTINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 73. BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 74. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 75. MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 76. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 77. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 78. AUSTRALIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 79. CHINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 80. INDIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 81. INDONESIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 82. JAPAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 83. MALAYSIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 84. PHILIPPINES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 85. SINGAPORE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 86. SOUTH KOREA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 87. TAIWAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 88. THAILAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 90. FRANCE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 91. GERMANY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 92. ITALY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 93. NETHERLANDS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 94. QATAR HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 95. RUSSIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 96. SAUDI ARABIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 97. SOUTH AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 98. SPAIN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 99. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 100. UNITED KINGDOM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 101. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET: SCORES
TABLE 102. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET: BUSINESS STRATEGY
TABLE 103. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET: PRODUCT SATISFACTION
TABLE 104. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET: RANKING
TABLE 105. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET: SHARE, BY KEY PLAYER, 2021
TABLE 106. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET: MERGER & ACQUISITION
TABLE 107. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 108. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 109. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET: INVESTMENT & FUNDING
TABLE 110. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 111. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET: LICENSE & PRICING
Note: Product cover images may vary from those shown
  • A-S Medication Solutions, LLC
  • AstraZeneca PLC
  • Bavarian Nordic A/S
  • Eyegene lnc. Ltd.
  • GlaxoSmithKline PLC
  • Inovio Pharmaceuticals Inc.
  • Johnson & Johnson
  • Merck Sharp & Dohme Corp.
  • Pfizer Inc.
  • Sanofi S.A.
Note: Product cover images may vary from those shown

Loading
LOADING...